Heron Therapeutics Inc ( (HRTX) ) has released its Q2 earnings. Here is a breakdown of the information Heron Therapeutics Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve medical care, particularly in the acute care and oncology sectors.
In its latest earnings report, Heron Therapeutics announced a Q2 2025 net revenue of $37.2 million, with a year-to-date revenue of $76.1 million. The company has reaffirmed its 2025 net revenue guidance of $153 million to $163 million and raised its full-year adjusted EBITDA guidance to $9.0 million – $13.0 million.
Key financial highlights include a record year-to-date adjusted EBITDA of $7.9 million and significant growth in product demand; ZYNRELEF demand increased by 6.3%, and APONVIE demand grew by 19% in Q2 2025 compared to Q1 2025. Heron also completed a comprehensive capital restructuring, reducing total debt and extending maturities to enhance financial flexibility.
Heron’s Acute Care franchise showed impressive revenue growth, with a 55.5% year-over-year increase in Q2 2025. The company is preparing for expanded commercial initiatives, including a dedicated sales team for ZYNRELEF and APONVIE, aimed at driving further growth and adoption.
Looking forward, Heron Therapeutics remains focused on accelerating the expansion of its core products and executing strategic priorities to drive sustainable growth and deliver long-term value to stakeholders.